Search the Community
Showing results for tags 'il-6'.
Linear scleroderma "en coup de sabre" with extensive brain involvement-Clinicopathologic correlations and response to anti-Interleukin-6 therapy. The interleukin-6 (IL-6) receptor inhibitor tocilizumab was used and the patient improved dramatically, likely reflecting the drug's effect on the replenishment of endothelial progenitor cells. PubMed, Orphanet J Rare Dis, 2019 May 16;14(1):110. (Also see En Coup de Sabre) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.